Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22745500 | 0.87 | POLB (0.40) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL22745249 | 0.84 | POLB (0.38) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL19935294 | 0.81 | POLB (0.33) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL22745239 | 0.79 | POLB (0.34) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL22745259 | 0.79 | POLB (0.34) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL19935363 | 0.77 | POLB (0.38) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL22745311 | 0.77 | POLB (0.34) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL19935308 | 0.76 | POLB (0.37) | POLBGAATDP1NPC1LMNA | |
| SCHEMBL22745380 | 0.75 | POLB (0.32) | POLBGAA | |
| SCHEMBL22745132 | 0.75 | POLB (0.33) | POLBGAATDP1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848372-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2021-07-14 | — | — | EP | disclosed |
| EP-3504214-B1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2020-12-02 | — | — | EP | disclosed |
| WO-2018042303-A1 | FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2018-03-08 | — | — | WO | disclosed |